Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Roche Holdings Ltd ADR (RHHBY)

Roche Holdings Ltd ADR (RHHBY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Tap the Weight-Loss Drug Market With These ETFs

The weight-loss drug market is heating up with the introduction of GLP-1 pills. Novo Nordisk’s NVO Wegovy and Eli Lilly’s LLY Zepbound have been dominating this market and several other companies are...

RHHBY : 39.6100 (+0.71%)
NVO : 132.06 (+0.05%)
LLY : 904.97 (-0.13%)
HRTS : 34.67 (+0.14%)
THNR : 27.38 (-0.07%)
OZEM : 28.15 (-0.60%)
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)

Telemedicine once seemed like it was going to revolutionize healthcare.

LLY : 904.97 (-0.13%)
PFE : 29.75 (-0.27%)
NVO : 132.06 (+0.05%)
TDOC : 9.09 (-0.22%)
AMZN : 186.43 (-0.24%)
NVDA : 113.37 (-1.92%)
SFIX : 4.14 (+0.98%)
VKTX : 64.45 (+2.40%)
ALT : 7.43 (-1.85%)
RHHBY : 39.6100 (+0.71%)
HIMS : 16.31 (+1.30%)
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label

Regeneron Pharmaceuticals, Inc. REGN announced that the FDA has approved blockbuster drug Dupixent (dupilumab) for the indication of chronic rhinosinusitis with nasal polyps (CRSwNP) for a broader population.The...

REGN : 1,138.81 (-0.69%)
SNY : 57.47 (+0.98%)
RHHBY : 39.6100 (+0.71%)
Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq

Roche RHHBY announced that the FDA has approved the subcutaneous (SC) formulation of the blockbuster immunotherapy drug Tecentriq (atezolizumab).The SC formulation was approved under the brand name Tecentriq...

NVS : 115.97 (+0.23%)
RHHBY : 39.6100 (+0.71%)
LLY : 904.97 (-0.13%)
Roche Stock to Benefit From Accu-Chek Smartguide Launch in Europe

Roche RHHBY is set to enter the competitive continuous glucose monitor (CGM) market in Europe following the CE mark approval of its Accu-Chek Smartguide in July.The Swiss pharmaceutical company plans to...

ABT : 114.88 (-2.75%)
RHHBY : 39.6100 (+0.71%)
ISRG : 482.09 (-0.25%)
DXCM : 69.46 (+0.75%)
Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735

Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right track.

MS : 99.30 (-0.54%)
LLY : 904.97 (-0.13%)
VKTX : 64.45 (+2.40%)
RHHBY : 39.6100 (+0.71%)
Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks

Large drug-maker stocks have witnessed a strong run this year, driven by positive pipeline news and regulatory approvals. The FDA has granted approval to 29 novel drugs this year. Innovation in the industry...

NVS : 115.97 (+0.23%)
RHHBY : 39.6100 (+0.71%)
PFE : 29.75 (-0.27%)
LLY : 904.97 (-0.13%)
Roche Stock Down on Concerns of Side-Effects From Its Obesity Drug

Roche RHHBY presented results of an early-stage study on its experimental obesity drug, CT-996, at the European Association for the Study of Diabetes annual meeting.CT-996 is an investigational, once-daily,...

RHHBY : 39.6100 (+0.71%)
NVO : 132.06 (+0.05%)
LLY : 904.97 (-0.13%)
Why Roche Holdings Stock Withered on Wednesday

The company had a dispiriting update to offer about an investigational drug.

NVO : 132.06 (+0.05%)
LLY : 904.97 (-0.13%)
RHHBY : 39.6100 (+0.71%)
Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals

Sanofi SNY and Regeneron REGN announced encouraging data from the confirmatory phase III LIBERTY-CUPID C study evaluating their blockbuster drug Dupixent (dupilumab) in chronicspontaneous urticaria (CSU)...

REGN : 1,138.81 (-0.69%)
SNY : 57.47 (+0.98%)
NVS : 115.97 (+0.23%)
RHHBY : 39.6100 (+0.71%)

Barchart Exclusives

3 Top Dividend Stocks to Buy This September
After today's jumbo rate cut from the Fed, here are three dividend stocks to bolster your portfolio. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar